<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35341417</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine</Title>
          <ISOAbbreviation>Ann Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Response to letter regarding: development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after <i>Helicobacter pylori</i> eradication.</ArticleTitle>
        <Pagination>
          <StartPage>856</StartPage>
          <EndPage>857</EndPage>
          <MedlinePgn>856-857</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2022.2053570</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mori</LastName>
            <ForeName>Hideki</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-8994-6163</Identifier>
            <AffiliationInfo>
              <Affiliation>Translational Research Center for Gastrointestinal Diseases (TARGID), University of Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsuzaki</LastName>
            <ForeName>Juntaro</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suzuki</LastName>
            <ForeName>Hidekazu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Med</MedlineTA>
        <NlmUniqueID>8906388</NlmUniqueID>
        <ISSNLinking>0785-3890</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CoiStatement>During the last 2 years, H.S. received scholarship funds from Astellas Pharm, Inc., Astra-Zeneca K.K., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Zeria Pharmaceutical Co., Ltd., joint research fund from Tosoh Corporation and service honoraria from Astellas Pharma, Inc., Astra-Zeneca K.K., EA Pharma Co., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Tsumura Co. and Zeria Pharmaceutical Co., Ltd.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35341417</ArticleId>
        <ArticleId IdType="pmc">PMC8959498</ArticleId>
        <ArticleId IdType="doi">10.1080/07853890.2022.2053570</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Yang H, Hu B.. 
Letter to the editor: development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication. Ann Med. 2022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35000515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori H, Suzuki H, Matsuzaki J, et al. . 
Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication. Ann Med. 2022;54(1):170–180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35000515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Take S, Mizuno M, Ishiki K, et al. . 
The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 2011;46(3):318–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21103997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Correa P, Piazuelo MB, Wilson KT.. 
Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105(3):493–498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2895407</ArticleId>
            <ArticleId IdType="pubmed">20203636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JWJ, Zhu F, Srivastava S, et al. . 
Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). Gut. 2021:gutjnl-2021-324057. doi:10.1136/gutjnl-2021-324057</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2021-324057</ArticleId>
            <ArticleId IdType="pubmed">33975867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawamura M, Uedo N, Koike T, et al. . 
Kyoto classification risk scoring system and endoscopic grading of gastric intestinal metaplasia for gastric cancer: multicenter observation study in Japan. Dig Endosc. 2022;34(3):508–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34415621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiiya T, Nakazato M, Mizuta M, et al. . 
Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87(1):240–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11788653</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
